Amazon sellers profit analytics that are accurate Provide detailed information about Amazon fees (e.g. FBA fee, commissions, PPC spend, return cost, promotion costs and your fixed costs (e.g. Virtual Assistant, Prep Center You can also view your data by time period (today or yesterday) and by product. Our flexible charts allow for quick and easy analysis of your Key Performance indicators. Everything can be customized: KPI's (e.g. sales, units profit, return costs etc. The output can be filtered by timeframe and granularity (e.g. last year by month, or last month by day). You can filter the view by product or marketplace (with multi-selection). You can view summary information and drill down into product details for each period. It's a clickable, smart P&L statement that allows you to focus on each parameter (e.g. amazon fees) for each time period.
Learn more

Epicor Kinetic is a cloud-first, AI-powered ERP platform for manufacturing environments that require a connected system for transactional, operational, and reporting workflows. The platform supports finance, supply chain, production, inventory, quality, service, analytics, project management, governance and compliance, and global business management. Functional coverage includes planning and scheduling, materials management, shop floor coordination, product management, CRM, field service, electronic reporting, and enterprise content management. Kinetic provides browser-based access, role-based workflows, integration and extensibility tools, IIoT-related capabilities, and deployment options for cloud, on-premises, or hybrid architectures. It can integrate with listed third-party systems for payroll, tax, labeling, procurement, warehouse processes, data capture, and quality workflows, including ADP Workforce Now, Avalara, BarTender, Sage, SourceDay, and Sovos. Epicor Prism adds AI-supported automation and decision support for selected workflows. Kinetic also supports operations across the Americas, EMEA, and APAC and is available in multiple languages, which can matter for distributed manufacturing organizations with regional or multinational requirements.
Learn more
Elucid
Enhance patient care by using the only objective, quantitative arterial analysis software validated through histology and based on CTA technology. This innovative tool employs ground-truth histological data to reveal the origins of myocardial ischemia, helping to assess risks for heart attacks and strokes. These critical events are often driven by unstable, non-obstructive plaques within the arteries that remain undetected and unaddressed. Traditional non-invasive diagnostic methods fall short, as they cannot penetrate deep into the arterial walls where heart disease begins to manifest. Elucid is leveraging advanced scientific imaging alongside artificial intelligence to facilitate rapid, reliable, and non-invasive diagnoses, ultimately leading to tailored treatment strategies for cardiovascular conditions and improved patient outcomes. With this histology-validated software, you can evaluate plaque composition and determine the risks of heart attacks and strokes with unmatched precision. This comprehensive, objective visualization of arterial health empowers healthcare providers to devise customized treatment approaches well before a patient arrives for hospital care, significantly enhancing the quality of healthcare delivery.
Learn more
Artrya
Artrya collaborates with healthcare facilities that treat chest pain patients to introduce innovative cardiovascular care models powered by artificial intelligence. This approach seamlessly incorporates high-prognostic plaque characteristics into the assessment of coronary artery disease. It enables swift evaluations of chest pain patients in both emergency and primary care environments. Our vision is a society free from the burden of heart attacks. Leveraging AI-generated insights from coronary computed tomography angiography (CCTA), we can rapidly and accurately classify chest pain patients based on the type and quantity of arterial plaque identified. This allows for quick identification of individuals with little to no coronary artery disease, ensuring that no underlying plaque issues could lead to significant cardiac events in the future. By recognizing early indicators of potential heart attacks, we can effectively confirm at-risk patients with acute or unusual chest pain who may require additional investigation and treatment. Ultimately, this advancement aims to enhance patient outcomes and foster a healthier community.
Learn more